Clinical Cancer Research Meeting Calendar Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yip, K. W.
Right arrow Articles by Liu, F.-F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yip, K. W.
Right arrow Articles by Liu, F.-F.
Clinical Cancer Research Vol. 12, 5726-5732, October 1, 2006
© 2006 American Association for Cancer Research


Imaging, Diagnosis, Prognosis

Prognostic Significance of the Epstein-Barr Virus, p53, Bcl-2, and Survivin in Nasopharyngeal Cancer

Kenneth W. Yip1,3, Wei Shi1,3, Melania Pintilie4, Joseph D. Martin1,2,3,7, Joseph D. Mocanu1,3, Derek Wong1,3, Christine MacMillan5, Pat Gullane6, Brian O'Sullivan2,7, Carlo Bastianutto1,3 and Fei-Fei Liu1,2,3,7

Authors' Affiliations: Departments of 1 Medical Biophysics and 2 Radiation Oncology, University of Toronto, 3 Division of Applied Molecular Oncology, Ontario Cancer Institute, 4 Clinical Study Coordination and Biostatistics, Ontario Cancer Institute/Princess Margaret Hospital, University Health Network, 5 Department of Pathology, Mt. Sinai Hospital, and Departments of 6 Surgical Oncology and 7 Radiation Oncology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada

Requests for reprints: Fei-Fei Liu, Department of Radiation Oncology, Princess Margaret Hospital/Ontario Cancer Institute, 610 University Avenue, Room 10-203, Toronto, Ontario, Canada M5G 2M9. Phone: 416-946-2123; Fax: 416-946-4586; E-mail: Fei-Fei.Liu{at}rmp.uhn.on.ca.

Purpose: Nasopharyngeal cancer (NPC) is a malignant epithelial carcinoma which is intimately associated with EBV. The latent presence of EBV affects the function of p53, Bcl-2, and survivin. We thus investigated the relationship between EBV status, p53, Bcl-2, and survivin in biopsy specimens from patients with primary NPC.

Experimental Design: Archival formalin-fixed, paraffin-embedded NPC biopsies were evaluated in 80 patients treated with curative radiation from a single institution. The presence of EBV was determined using EBER in situ hybridization, whereas p53, Bcl-2, and survivin were assessed using immunohistochemistry.

Results: The majority of NPC specimens in this patient cohort were EBER-positive (64 of 78, or 82%), which in turn, was significantly associated with ethnicity (P = 0.0007), and WHO subtype 2A/2B (P = 0.04). EBER-positive tumors were also associated with p53 (P = 0.002), Bcl-2 (P = 0.04), and nuclear survivin (P = 0.03) expression. Patients with EBER-positive NPC fared better, with a 10-year overall survival of 68% versus 48% for EBER-negative patients (P = 0.03). For nuclear survivin, patients with either low or high nuclear survivin fared worse than patients with intermediate survivin expression (P = 0.05), suggesting that there is an optimal proportion of survivin-expressing cells for best function and clinical outcome.

Conclusions: With an extended median follow-up time of 11.4 years, EBV status remains a strong predictor for overall survival in NPC. EBV-positive NPC has strong molecular associations with p53, Bcl-2, and survivin expression. Furthermore, we provide clinical data revealing the potentially dual nature of survivin in predicting clinical outcome.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
A. B.Y. Hui, S. Yue, W. Shi, N. M. Alajez, E. Ito, S. R. Green, S. Frame, B. O'Sullivan, and F.-F. Liu
Therapeutic Efficacy of Seliciclib in Combination with Ionizing Radiation for Human Nasopharyngeal Carcinoma
Clin. Cancer Res., June 1, 2009; 15(11): 3716 - 3724.
[Abstract] [Full Text] [PDF]


Home page
Acta Biochim Biophys SinHome page
W. Zhang, Z. Zeng, Y. Zhou, W. Xiong, S. Fan, L. Xiao, D. Huang, Z. Li, D. Li, M. Wu, et al.
Identification of aberrant cell cycle regulation in Epstein-Barr virus-associated nasopharyngeal carcinoma by cDNA microarray and gene set enrichment analysis
Acta Biochim Biophys Sin, May 1, 2009; 41(5): 414 - 428.
[Abstract] [Full Text] [PDF]


Home page
J. Mol. Diagn.Home page
M. L. Gulley and W. Tang
Laboratory Assays for Epstein-Barr Virus-Related Disease
J. Mol. Diagn., July 1, 2008; 10(4): 279 - 292.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.